secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001493152-25-011441
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech reports positive mid-year Phase 2 data for Ampligen+Imfinzi in pancreatic cancer
--------------------------------------------------------------------------------

- No grade ≥2 immune-related or systemic toxicities reported across 14 enrolled patients.
- 3 of 14 patients (21%) had PFS >6 months; 3 additional patients not yet progressed at cutoff.
- Of 11 evaluable patients, 7 (64%) achieved overall survival >6 months.
- Combination of Ampligen (rintatolimod) and AstraZeneca's Imfinzi (durvalumab) studied post-FOLFIRINOX.
- Final analysis pending immune-monitoring data from paired biopsies and blood samples.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315225011441/0001493152-25-011441-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315225011441/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011441

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer